AAM
TVRD

Aberdeen Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Aberdeen Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-24,712
Closed -$7.46M – 736
2014
Q3 		$7.46M Hold
24,712
– – 0.02% 352
2014
Q2 		$15.1M Buy
+24,712
New +$13.3M 0.03% 272

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DPA
Devon Park Associates $30.8M AUM 0.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Aberdeen Asset Management's TVRD Position: Q4 2014 in Review

Aberdeen Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2014, closing a stake of 24,712 shares — an estimated $7.46M sold.

Aberdeen Asset Management first reported a position in TVRD in Q2 2014 and held it in 2 quarters. The position peaked at $15.1M in Q2 2014. 56 funds tracked by Wall St. Rank hold TVRD as of Q4 2014.

  • Aberdeen Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Aberdeen Asset Management sold 24,712 Tvardi Therapeutics shares in Q4 2014, an estimated $7.46M.
  • Aberdeen Asset Management first reported a position in Tvardi Therapeutics in Q2 2014 and held it in 2 quarters.
  • Aberdeen Asset Management's Tvardi Therapeutics position peaked at $15.1M in Q2 2014.
  • 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2014.

Based on Aberdeen Asset Management's 13F filing for Q4 2014, filed 13 Jan 2015.